权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

2016 Lipoprotein Metabolism Gordon Research Conference and Gordon Research Seminar

2016年脂蛋白代谢戈登研究会议暨戈登研究研讨会

基本信息

批准号：
9119203
负责人：
JOHN S PARKS
金额：
$ 2.5万
依托单位：
GORDON RESEARCH CONFERENCES
依托单位国家：
美国
项目类别：
财政年份：
2016
资助国家：
美国
起止时间：
2016-06-01 至 2017-05-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/9119203
关键词：
Accounting Address African American Alzheimer&apos s Disease Animal Model Antibodies Area Atherosclerosis Basic Science Biochemistry Bioinformatics Biological Biological Models Biology Blood Vessels Cardiovascular Diseases Catabolism Cells Chronic Disease Clinical Collaborations Consultations Coronary heart disease Country Development Diabetes Mellitus Diagnosis Dyslipidemias Ensure Event Fostering Genetic Genetic study Goals Heart Diseases High Density Lipoproteins Hour Human Hyperlipidemia Individual Insulin Resistance International Intestines Knowledge Lipids Lipoproteins Liver Metabolism Mission Molecular National Heart, Lung, and Blood Institute Neurodegenerative Disorders New Hampshire Oral Pathogenesis Patients Pharmaceutical Preparations Physiological Processes Physiology Postdoctoral Fellow Prevention Primary Prevention Process Proteomics Public Health Qualifying Relationship-Building Reporting Research Research Personnel Residual state Risk Schedule Science Scientific Inquiry Scientist Secondary Prevention Site Systems Biology Technology Therapeutic Time Training Translating Translational Research Translations Woman abstracting cardiovascular risk factor career development design gender diversity graduate student human genomics human population study improved in vivo interest knowledge base lipid metabolism lipid transport meetings novel therapeutic intervention posters programs public health relevance social success symposium unpublished works

项目摘要

DESCRIPTION (provided by applicant): We request partial support for the 2016 Lipoprotein Metabolism Gordon Research Conference (GRC) and Gordon Research Seminar (GRS) to be held at Waterville Valley Conference Center in New Hampshire on June 12-17, 2016. The Chair, Dr. John Parks, in consultation with past chairs, the 2016 Co-Chairs (Drs. Alan Remaley and Cheryl Wellington), and leaders in the field, have planned nine oral sessions for the GRC: Session 1- Lipid Transport and Catabolism, Session 2- Lipoproteins and the Vascular Wall, Session 3- Keynote Address on Lipoprotein Metabolism and Coronary Heart Disease and short talks, Session 4- In vivo Physiology of Lipid Metabolism, Session 5- Liver and Intestinal Lipid/Lipoprotein Metabolism, Session 6- HDL function, Session 7- Genetics of Lipid/Lipoprotein Metabolism, Session 8- Intracellular Lipid Metabolism, and Session 9- Therapeutics for Cardiovascular and Neurodegenerative Diseases. The GRC will be preceded by the Lipoprotein Metabolism GRS, an international forum for the presentation and discussion of cutting-edge research by graduate students and postdoctoral fellows. Our conference satisfies all aspects of the NHLBI mission. 1) We bring together international leaders in lipoprotein metabolism, a physiological process that accounts for more than 30% of global cardiovascular risk burden. 2) Gender and diversity-related issues in genetics, biology, biochemistry, and clinical manifestations of lipoproteins are also addressed, acknowledging the complexity of these issues. Also, 13 of the 33 accepted speakers are women (39%), including the Keynote Speaker, Dr. Helen Hobbs, one is African American (3%), and 3 (9%) are young investigators. In addition, eight of the accepted speakers are international, representing six countries outside the US. 3) Our conference has been carefully coordinated to include a diversity of research related to the causes, prevention, diagnosis and treatment of dyslipidemias, cardiovascular disease, and other chronic diseases, such as insulin resistance, Alzheimer's disease, and hepatosteatosis. 4) In keeping with the NHLBI's priority on prevention, key aspects of primary and secondary prevention of cardiovascular disease currently in routine clinical use (e.g. statin drugs) were firt reported at our past meetings. 5) The Chair and Co-Chairs place the highest priority on participation by individuals early in their training and career development. Narrative: The 2016 Lipoprotein Metabolism Gordon Research Conference will bring together national and international leaders in lipoprotein metabolism, which underlies more than 30% of the global risk burden of cardiovascular disease, a subject of critical